oalib

OALib Journal期刊

ISSN: 2333-9721

费用：99美元

投稿

时间不限

( 2673 )

( 2672 )

( 2208 )

( 2024 )

自定义范围…

匹配条件： “Nanda K” ，找到相关结果约178485条。
列表显示的所有文章，均可免费获取
第1页/共178485条
每页显示 条
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX mesalamine
Nanda K, Moss AC
Clinical Pharmacology: Advances and Applications , 2012, DOI: http://dx.doi.org/10.2147/CPAA.S26556
Abstract: ate on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX mesalamine Review (2527) Total Article Views Authors: Nanda K, Moss AC Published Date July 2012 Volume 2012:4 Pages 41 - 50 DOI: http://dx.doi.org/10.2147/CPAA.S26556 Received: 09 May 2012 Accepted: 13 June 2012 Published: 25 July 2012 Kavinderjit Nanda, Alan C Moss Center for Inflammatory Bowel Disease, BIDMC/Harvard Medical School, Boston, MA, USA Abstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop. The goals of management are to induce and maintain clinical remission and to screen for complications of this disease. Mesalamine is a 5-aminosalicylic acid compound that is the first-line therapy to induce and maintain clinical remission in patients with mild-to-moderate UC. For patients who are refractory to mesalamine or have more severe disease, steroids, azathioprine/mercaptopurine, cyclosporine, or infliximab may be used, induce and/or maintain remission. The various formulations of mesalamine available are primarily differentiated by the methods of delivery of the active compound of the drug to the colon. Mesalamine with Multi-Matrix System (MMX) technology (Cosmo SpA, Milan, Italy) is an oral (1.2 g), once-daily tablet formulation of mesalamine used for the treatment of UC (Lialda or Mezavant , Shire Pharmaceuticals Inc, Wayne, PA). In clinical studies, MMX mesalamine (taken as a once-daily dose of 2.4 or 4.8 g) effectively induced and maintained clinical remission in patients with active mild-to-moderate UC. The overall safety profile of MMX mesalamine is similar to other oral mesalamine formulations. The use of such once-daily formulations has led to intense interest in whether simplified pill regimens can improve patient adherence to mesalamine therapy.
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
Nanda K,Moss AC
Clinical Pharmacology: Advances and Applications , 2012,
Abstract: Kavinderjit Nanda, Alan C MossCenter for Inflammatory Bowel Disease, BIDMC/Harvard Medical School, Boston, MA, USAAbstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop. The goals of management are to induce and maintain clinical remission and to screen for complications of this disease. Mesalamine is a 5-aminosalicylic acid compound that is the first-line therapy to induce and maintain clinical remission in patients with mild-to-moderate UC. For patients who are refractory to mesalamine or have more severe disease, steroids, azathioprine/mercaptopurine, cyclosporine, or infliximab may be used, induce and/or maintain remission. The various formulations of mesalamine available are primarily differentiated by the methods of delivery of the active compound of the drug to the colon. Mesalamine with Multi-Matrix System (MMX) technology (Cosmo SpA, Milan, Italy) is an oral (1.2 g), once-daily tablet formulation of mesalamine used for the treatment of UC (Lialda or Mezavant , Shire Pharmaceuticals Inc, Wayne, PA). In clinical studies, MMX mesalamine (taken as a once-daily dose of 2.4 or 4.8 g) effectively induced and maintained clinical remission in patients with active mild-to-moderate UC. The overall safety profile of MMX mesalamine is similar to other oral mesalamine formulations. The use of such once-daily formulations has led to intense interest in whether simplified pill regimens can improve patient adherence to mesalamine therapy.Keywords: mesalamine, 5-ASA, ulcerative colitis, inflammatory bowel disease
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum]
Nanda K,Moss AC
Clinical Pharmacology: Advances and Applications , 2013,
Abstract: Nanda K, Moss AC.Clinical Pharmacology: Advances and Applications. 2012, 4:41–50.The authors apologize for errors on Tables 1, 2, and 3.Table1Citation 40, Hussain et al, should have been citation 44, Shire US Inc.Table 2Lichtenstein et al data, the confidence interval (CI) of the odds ratio for achieving remission with MMX mesalamine 1.2 g twice daily (1.44–8.41) should be listed as a 97.5% CI rather than a 95% CI.Table 3Prantera et al, the MMX mesalamine 2.4 g once daily cohort should have an N value of 156, not 162, and the 12-month relapse rate should be 25.0%, not 15.0%.Pramtera et al, the Asacol 2.4 g once daily cohort should be labeled "Asacol 2.4 g/day twice daily", and should have an N value of 167, not 156.Kane et al, the N value should be 194, not 167.Read the original article
Blood coagulation factor VIII: An overview
R K Nanda
- , 2003,
Abstract:
Effect of Annealing Temperature on the Structural and Magnetic Properties of NiFe2O4 Nanoferrites  [PDF]
A. Sangeetha, K. Vijaya Kumar, G. Nanda Kumar
Advances in Materials Physics and Chemistry (AMPC) , 2017, DOI: 10.4236/ampc.2017.72003
Abstract: Nanocrystalline NiFe2O4 spinel ferrites were synthesized by sol-gel method. The structural and magnetic properties were investigated using X-ray diffraction (XRD), Fourier Transform Infrared (FTIR) spectroscopy, Scanning Electron Microscopy (SEM) and Vibrating Sample Magnetometer (VSM). Annealing temperature showed prominent effect on the grain size. The average grain size of NiFe2O4 was observed to increase from 31 nm to 54 nm as the annealing increased from 500℃ to 1000℃. The IR spectra showed the absorption bands corresponding to stretching of tetrahedral and octahedral bands. The magnetic properties were observed to depend strongly on the annealing temperature.
The devil is in Asymmetries (Rough Version)
Edinah K. Gnang,Vidit Nanda
Computer Science , 2012,
Abstract: We formally investigate some computational obstacles to tractability of computing the variety determined by K complex polynomials in N boolean variables. We show that using algebraic methods for solving combinatorial problems, the obstacles to tractability lies in the order of magnitude of asymmetries admitted by the given system of equations.
Electrical characteristics of multiwalled carbon nanotube arrays and influence of pressure
L. T. Singh,K. K. Nanda
AIP Advances , 2012, DOI: 10.1063/1.3702777
Abstract: We have investigated the current-voltage characteristics of carbon nanotube arrays and shown that the current through the arrays increases rapidly with applied voltage before the breakdown occurs. Simultaneous measurements of current and temperature at one end of the arrays suggest that the rapid increase of current is due to Joule heating. The current through the array and the threshold voltage are found to increase with decreasing pressure.
Specific heat of high temperature superconductors: Role of $\mid ψ \mid^{4}$ term in Ginzburg--Landau free energy
Bikash. Ch. Gupta,K. K. Nanda
Physics , 1996, DOI: 10.1016/0921-4534(96)00300-0
Abstract: We have derived the expression for the specific heat by using Ginzburg-Landau (GL) theory by taking $\mid \psi \mid^{4}$ into account in the Hartree approximation. Without this term, the specific heat diverges at $T=T_{c}(B)$. It is also shown that width and shape of the transition depends on the value of $\alpha$ and $\beta$, the coefficients in the GL free energy.
Synthesis of one-dimensional N-doped Ga2O3 nanostructures: different morphologies and different mechanisms
K K Nanda,S C Vanithakumari
- , 2011,
Abstract:
Photoperiodic control of extension growth, bud dormancy and flowering ofNerium indicum Mill. andThevetia peruviana Schum.
K K Nanda,Kushal Singh,Surinder Kumar
- , 1982,
Abstract:
第1页/共178485条
每页显示 条


Home
Copyright © 2008-2020 Open Access Library. All rights reserved.